Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Janus kinase 2 is a non-receptor tyrosine kinase. It is involved in various processes such as cell growth, development, differentiation, or histone modifications. It mediates essential signaling events in both innate and adaptive immunity. It plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone, prolactin, leptin, erythropoietin, thrombopoietin or type II receptors including IFN-alpha, IFN-beta, IFN-gamma, and multiple interleukins. It plays a role in cell cycle by phosphorylating CDKN1B.

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) pipeline Target constitutes close to 36 molecules. Out of which approximately 26 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Archived (Marketed), Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 1, 6, 5, 2, 7 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 5 and 5 molecules, respectively.

Report covers products from therapy areas Oncology, Immunology, Dermatology, Respiratory, Infectious Disease, Hematological Disorders, Metabolic Disorders, Musculoskeletal Disorders, Cardiovascular, Central Nervous System, Genetic Disorders, Genito Urinary System And Sex Hormones, Ophthalmology and Women's Health which include indications Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Graft Versus Host Disease (GVHD), Rheumatoid Arthritis, Alopecia Areata, Atopic Dermatitis (Atopic Eczema), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Autoimmune Disorders, Coronavirus Disease 2019 (COVID-19), Glioblastoma Multiforme (GBM), Inflammation, Myelodysplastic Syndrome, Asthma, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Chronic Myelomonocytic Leukemia (CMML), Dermatitis (Eczema), Essential Thrombocythemia, Head And Neck Cancer, Hemophagocytic Lymphohistiocytosis, Leukemia, Peripheral T-Cell Lymphomas (PTCL), Plaque Psoriasis (Psoriasis Vulgaris), Polycythemia Vera, Sicca Syndrome (Sjogren), Solid Tumor, Unspecified Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Respiratory Distress Syndrome, Aicardi-Goutieres Syndrome (AGS), Allergies, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Anaplastic Astrocytoma, Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Angiosarcoma, Ankylosing Spondylitis (Bekhterev's Disease), Auto Inflammatory Disease, Breast Hyperplasia, Bronchiolitis Obliterans, Central Nervous System (CNS) Tumor, Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE), Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis), Chronic Kidney Disease (Chronic Renal Failure), Chronic Lymphocytic Leukemia (CLL), Chronic Obstructive Pulmonary Disease (COPD), Colorectal Cancer, Coronavirus Disease 2019 (COVID-19) Associated Cytokine Release Syndrome, Cutaneous T-Cell Lymphoma, Diabetic Macular Edema, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Epstein-Barr Virus (HHV-4) Infections, Focal Segmental Glomerulosclerosis (FSGS), Gallbladder Cancer, Gastrointestinal Tract Cancer, Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease), Gliosarcoma, Hand Dermatitis, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Hematopoietic Stem Cell Transplantation, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Hypereosinophilic Syndrome, Hypopharyngeal Cancer, Idiopathic Pulmonary Fibrosis, Juvenile Arthritis, Keratoconjunctivitis Sicca (Dry Eye), Laryngeal Cancer, Lipodystrophy (Lipoatrophy), Liver Cancer, Melanoma, Mild Cognitive Impairment, Mycosis Fungoides, Myeloproliferative Disorders, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Pancreatic Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Pneumonia, Polymyalgia Rheumatica (PMR), Prurigo, Psoriasis, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Salivary Gland Cancer, Secondary Myelofibrosis, Sezary Syndrome, Soft Tissue Sarcoma, Squamous Cell Carcinoma, Systemic Idiopathic Juvenile Arthritis, Systemic Sclerosis (Scleroderma), Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), Thrombocythemia Myelofibrosis, Thyroid Cancer, Triple-Negative Breast Cancer (TNBC), Uterine Cancer and Vitiligo.

The latest report Tyrosine Protein Kinase JAK2 - Drugs In Development, 2022, outlays comprehensive information on the Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2)
• The report reviews Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
• The report assesses Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics

Reasons to Buy

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Show more